A phase II study of irinotecan in patients with advanced renal cell carcinoma

Cancer

Volumn 98, Issue 1, 2003, Pages 61-65

  Fizazi, Karim ^a   Rolland, Frédéric ^b   Chevreau, Christine ^c   Droz, Jean Pierre ^d   Mery Mignard, Dominique ^e   Culine, Stéphane ^f   Escudier, Bernard ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d CENTRE LÉON BÉRARD   (France)

^e SANOFI   (France)

^f CENTRE VAL D AURELLE   (France)

Author keywords

Chemotherapy; Immunotherapy; Irinotecan; Metastases; Renal cell cacinoma

Indexed keywords

ALPHA INTERFERON; ANTIEMETIC AGENT; ATROPINE; INTERLEUKIN 2; IRINOTECAN; LOPERAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTHEMIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, RENAL CELL; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037665007     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11474     Document Type: Article

References (25)

1. Menegoz F, Black RJ, Arveux P, et al. Cancer incidence and mortality in France in 1975-95. Eur J Cancer Prev. 1997;6:442-466.
2. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.
3. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-1659.
4. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med. 1998;338:1272-1278.
5. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18:1928-1935.
6. Negrier S, Caty A, Lesimple T, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d'Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2000;18:4009-4015.
7. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol. 2000;27:177-186.
8. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163:408-417.
9. Berg WJ, Schwart LH, Amsterdam A, et al. A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Invest New Drugs. 1997;15:353-355.
10. Pagliaro L, Daliani D, Amato R, et al. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer. 2000;89:615-618.
11. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18:2972-2980.
12. Vaishampayan U, Flaherty L, Du W, Hussain M. Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma. Cancer. 2001;92:519-523.
13. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-914.
14. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-1047.
15. Rochlitz CF, Lobeck H, Peter S, et al. Multiple drug resistance gene expression in human renal cell cancer is associated with the histologic subtype. Cancer. 1992;69:2993-2998.
16. Naito S, Sakamoto N, Kotoh S, Goto K, Matsumoto T, Kumazawa J. Expression of P-glycoprotein and multidrug resistance in renal cell carcinoma. Eur Urol. 1993;24:156-160.
17. Gamelin E, Mertins SD, Regis JT, et al. Intrinsic drug resistance in primary and metastatic renal cell carcinoma. J Urol. 1999;162:217-224.
18. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. Antitumor effect of CPT-11, a new derivative of camptoth-ecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol. 1988;21:71-74.
19. Fleming TR. One-sample multistage testing procedure for Phase II clinical trials. Biometrics. 1982;38:143-151.
20. Miki T, Nonomura N, Takaha N, et al. Antitumor effect of irinotecan hydrochloride (CPT-11) on human renal tumors heterotransplanted in nude mice. Int J Urol. 1998;5:370-373.
21. Ramp U, Mahotka C, Kalinski T, Ebel E, Gabbert HE, Gerharz CD. Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types. Anticancer Res. 2001;21:3509-3517.
22. Law TM, Ilson DH, Motzer RJ. Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs. 1994;12:143-145.
23. Le Cesne A, Vassal G, Farace F, et al. Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma? J Immunother. 1999;22:268-277.
24. Rini BI, Vogelzang NJ, Dumas MC, Wade JL III, Taber DA, Stadler WM. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000;18:2419-2426.
25. Childs R, Chernoff A, Contentin N, et al. Regression of met-astatic renal-cell carcinoma after nonmyeloablative alloge-neic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750-758.